Related Experiment Video

Updated: Sep 26, 2026

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis

J Killestein1, E L J Hoogervorst, M Reif

  • 1Department of Neurology, VU Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands. J.Killestein@vumc.nl

Journal of Neuroimmunology
|April 2, 2003
PubMed

Insights

This study investigated cannabinoids in multiple sclerosis (MS) patients. Results suggest cannabinoids may have pro-inflammatory effects, potentially modifying MS disease progression.

Area of Science:

  • Immunology
  • Neuroscience
  • Pharmacology

Background:

  • Cannabinoids are known to modulate immune cell function.
  • Multiple Sclerosis (MS) is an autoimmune disease affecting the central nervous system.
  • Understanding cannabinoid effects on immune function in MS is crucial.

Purpose of the Study:

  • To investigate the in vivo effects of oral cannabinoids on immune function in patients with Multiple Sclerosis.
  • To measure changes in cytokine profiles and immune cell responses during cannabinoid treatment.

Main Methods:

  • The study involved 16 patients diagnosed with Multiple Sclerosis.
  • Patients were treated with oral cannabinoids derived from cannabis plant extract.
  • Immune function was assessed by measuring cytokine levels (TNF-alpha, IL-12p40) in whole blood and plasma samples.

Main Results:

  • A modest increase in Tumor Necrosis Factor-alpha (TNF-alpha) was observed in LPS-stimulated whole blood during cannabinoid treatment (p=0.037).
  • No significant changes were noted in other measured cytokines.
  • Patients experiencing a high number of adverse events showed a significant increase in plasma Interleukin-12p40 (IL-12p40) (p=0.002).

Conclusions:

  • Cannabinoid treatment in MS patients may lead to pro-inflammatory changes.
  • These findings suggest a potential disease-modifying role for cannabinoids in MS, possibly through immune modulation.
  • Further research is warranted to elucidate the complex interactions between cannabinoids and the immune system in MS.

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...